CG Oncology reports 41.8% 24-month CR in Phase 3 BOND-003 for cretostimogene

CG Oncology, Inc.

24-month CR rate of 41.8% (46/110) in BCG-unresponsive HR NMIBC; 12 additional CRs since April 2025 AUA.
90% of 12-month responders remained disease-free at 24 months; 96.6% free from progression to muscle-invasive disease.
No Grade 3+ TRAEs or deaths; median TRAE resolution 1 day; 97.3% completed all treatments.
Company plans BLA submission for cretostimogene in HR NMIBC unresponsive to BCG in Q4 2025.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.